Biotech Values

[DewDiligence]

First thoughts on MNTA-BAX FoB partnership:

I’m fine with the financial terms—to the extent that they’ve been sketchily disclosed—but I don’t like BAX as the partner. BAX strikes me as firm that makes more than its share of mistakes for a medium-sized biotech and is habitually preoccupied with fighting regulatory fires such as manufacturing deficiencies and product recalls.

Maybe MNTA’s know-how will ensure BAX’s success in this endeavor, but I would have much preferred a partner such as PFE or SNY.

I’ll have more to say after the CC tomorrow.